Use of systemic steroid after successful macular surgery in eyes with epiretinal membrane: A randomized, controlled clinical study

Eye

Volumn 25, Issue 10, 2011, Pages 1284-1293

  Ritter, M ^a   Sacu, S ^a   Matt, G ^a   Dunavolgyi R ^a   Buhl W ^a   Prunte C ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

epiretinal membrane; macular surgery; optical coherence tomography; systemic steroid therapy

Indexed keywords

DEXAGENTA; DEXAMETHASONE PLUS GENTAMICIN; KETOROLAC TROMETAMOL; MYDRIATIKUM AGEPHA; PANTOPRAZOLE; PHENYLEPHRINE; PREDNISOLONE; TROPICAMIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINA THICKNESS; CLINICAL ARTICLE; CONTINUING EDUCATION; CONTROLLED STUDY; CONVALESCENCE; DISEASE CLASSIFICATION; EPIRETINAL MEMBRANE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MEDICAL EDUCATION; MORPHOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STEROID THERAPY; THICKNESS; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 80054087111     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.190     Document Type: Article

References (27)

1. Gandorfer A, Rohleder M, Kampik A. Epiretinal pathology of vitreomacular traction syndrome. Br J Ophthalmol 2002; 86: 902-909.
2. Massin P, Allouch C, Haouchine B, Yoshimura N. Optical coherence tomography of idiopathic macular epiretinal membranes before and after surgery. Am J Ophthalmol 2000; 130: 732-739.
3. Michalewski J, Michalewska Z, Cisiecki S, Nawrocki J. Morphologically functional correlations of macular pathology connected with epiretinal membrane formation in spectral optical coherence tomography (SOCT). Graefes Arch Clin Exp Ophthalmol 2007; 245: 1623-1631.
4. Pesin SR, Olk RJ, Grand MG, Boniuk I, Arribas NP, Thomas MA et al. Vitrectomy for premacular fibroplasia. Prognostic factors, long-term follow-up, and time course of visual improvement. Ophthalmology 1991; 98: 1109-1114.
5. Schwab F. Cortison und Auge. Wr Med Wochenschrift 1958; 108: 839-842.
6. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425-427.
7. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust NZJ Ophthalmol 1998; 26: 277-281.
8. Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathyFis it anything more than wound healing at a wrong place? Int Ophthalmol 1990; 14: 105-117.
9. Wiedemann P. Drug treatment of proliferative vitreoretinopathy. Fortschr Ophthalmol 1989; 86: 115-120.
10. Stanbury RM, Graham EM. Systemic corticosteroid therapyFside effects and their management. Br J Ophthalmol 1998; 82: 704-708.
11. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol 2003; 12: 667-673.
12. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598.
13. Fine HF, Iranmanesh R, Iturralde D, Spaide RF. Outcomes of 77 consecutive cases of 23-gauge transconjunctival vitrectomy surgery for posterior segment disease. Ophthalmology 2007; 114: 1197-1200.
14. Gupta OP, Ho AC, Kaiser PK, Regillo CD, Chen S, Dyer DS et al. Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol 2008; 146: 193-197.
15. Tewari A, Shah GK, Fang A. Visual outcomes with 23-gauge transconjunctival sutureless vitrectomy. Retina 2008; 28: 258-262.
16. Gordon DM, McLean JM. Effects of pituitary adrenocorticotropin hormone (ACTH) therapy in ophthalmic conditions. JAMA 1950; 142: 1271-1276.
17. Olson JA, Steffensen EN, Margulis RR, Smith RW, Whitney EL. Effect of ACTH on certain inflammatory diseases of the eye: A preliminary report. JAMA 1950; 142: 1276-1278.
18. Woods AC. Clinical and experimental observations on the use of ACTH and cortisone in ocular inflammatory disease. Am J Ophthalmol 1950; 33: 1325-1349.
19. Ruhmann AG, Berliner DL. Influence of steroids on fibroblasts. II. The fibroblast as an assay system for topical antiinflammatory potency of corticosteroids. J Invest Dermatol 1967; 49: 123-130.
20. Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468-471.
21. Bynoe LA, Weiss JN. Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol 2003; 135: 382-384.
22. Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosisFa controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol 1982; 219: 268-271.
23. Valone Jr. J, Moser D. Management of rhegmatogenous retinal detachment with macula detached. Steroids, choroidal detachment, and acuity. Ophthalmology 1986; 93: 1413-1417.
24. Konstantinidis L, Berguiga M, Beknazar E, Wolfensberger TJ. Anatomic and functional outcome after 23-gauge vitrectomy, peeling, and intravitreal triamcinolone for idiopathic macular epiretinal membrane. Retina 2009; 29: 1119-1127.
25. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-340.
26. Zkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005; 40: 63-68.
27. Tsujikawa A, Fujihara M, Iwawaki T, Yamamoto K, Kurimoto Y. Triamcinolone acetonide with vitrectomy for treatment of macular edema associated with branch retinal vein occlusion. Retina 2005; 25: 861-867.